Investor Presentation - First Six Months of 2021

24 Investor presentation First six months of 2021 Continued single digit volume growth within the insulin segments globally Novo NordiskⓇ tMU Long-acting insulin Premix insulin Fast-acting insulin tMU tMU 250 CAGR volume1: 4.5% 100% 160 CAGR volume1: 1.5% 100% 240 MI penetration²: 75.2% MI penetration²: 48.3% CAGR volume1: 4.5% MI penetration²: 77.2% 100% 200 200 80% 80% 80% 120 160 150 60% 60% 60% 00 80 120 100 50 40% 40 20% 40% 40% 80 20% 20% 40 0% 0 0% 0 0% May May May May May 2021 2016 2021 2016 2021 Segment volume -Ryzodeg Ⓡ -NovoMix® 30 -Combined Segment volume -NovoRapidⓇ FiaspⓇ Combined 0 May 2016 Segment volume Ⓡ Levemir -Tresiba Combined 1 CAGR for 5-year period 2 Includes new-generation insulin. tMU: Thousand mega units; NN: Novo Nordisk Note: Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology. Source: IQVIA MAT, May 2021 volume figures

View entire presentation